(Reuters) – Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, hurt by higher manufacturing costs and a $2.8 billion acquisition-related charge that sent the U.S. drugmaker’s shares down more than 10% ahead of the launch market.

The company also saw sales of its popular weight loss and diabetes drugs below analyst expectations, which it attributed to declines in inventories in the wholesale channel.

Lilly has invested billions of dollars to expand production of Mounjaro and Zepbound, known chemically as tirzepatid, including about $7 billion at its Indiana plant and plants in Ireland.

Mounjaro’s quarterly sales were $3.11 billion, and Zepbound’s revenue was $1.26 billion.

Lilly’s drug is sold under the brand name Mounjaro for both diabetes and weight loss outside the United States

Analysts predicted average sales for the quarter of $4.20 billion for Mounjaro and $1.69 billion for Zepbound. They expect drugs to make a total of $19 billion this year.